The newly defined molecular mechanism by which rapamycin suppresses proliferation via inhibiting abnormally elevated CDK1 and cyclins offers clues to new molecular targets for ADPKD treatment. Here, CDK1 is linked to autosomal dominant polycystic kidney disease.